FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Gives Gibson a Rare Pediatric Disease Designation

[ Price : $8.95]

FDA grants Gibson Oncology a Rare Pediatric Disease Designation for LMP-400, the companys novel small molecule topoisomerase 1inhi...

FDA Works With Pfizer on Animal Opioid Supply

[ Price : $8.95]

The Center for Veterinary Medicine works with Pfizer to keep a supply of injectable opioids available in the U.S. veterinary marke...

Support for Minimal Residual Disease Guidance

[ Price : $8.95]

Stakeholders praise an FDA draft guidance on use of minimal residual disease as a biomarker in developing drugs to treat blood can...

Q&A Guide on Biosimilar Development

[ Price : $8.95]

Federal Register notice: FDA makes available a final guidance entitled Questions and Answers on Biosimilar Development and the BPC...

Guide on Deemed To Be a License BLA Interpretation

[ Price : $8.95]

Federal Register notice: FDA announces the availability of a final guidance entitled Interpretation of the Deemed To Be a License ...

Draft Guide on Deemed to be a License BLAs

[ Price : $8.95]

Federal Register notice: FDA announces the availability of a draft guidance entitled The Deemed to be a License Provision of the B...

CGMP Integrity and Compliance Q&A Guidance

[ Price : $8.95]

FDA issues a question-and-answer guidance on data integrity and compliance with drug CGMPs.

Guidance on PMA, BLA User Fees and Refunds

[ Price : $8.95]

FDA issues a guidance explaining user fees and refunds for PMAs and some device BLAs as outlined in the MDUFA 4 agreement.

Dont Use 2 HelloCig E-Liquids: FDA

[ Price : $8.95]

FDA cautions consumers that two HelloCig e-liquids illegally contain undeclared prescription drug active ingredients used to treat...

U.S. Should OK Discovery in FCA Materiality Cases: Analysis

[ Price : $8.95]

Three Fried Frank attorneys say the Justice Department must allow discovery on False Claims Act questions of materiality if the go...